➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Moodys
McKesson
Baxter
Boehringer Ingelheim

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 212320


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 212320 describes ACCRUFER, which is a drug marketed by Shield Tx and is included in one NDA. There are three patents protecting this drug. Additional details are available on the ACCRUFER profile page.

The generic ingredient in ACCRUFER is ferric maltol. There are twenty drug master file entries for this compound. Additional details are available on the ferric maltol profile page.
Summary for 212320
Tradename:ACCRUFER
Applicant:Shield Tx
Ingredient:ferric maltol
Patents:3
Generic Entry Opportunity Date for 212320
Generic Entry Date for 212320*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength30MG IRON
Approval Date:Jul 25, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 25, 2024
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:  Start TrialPatent Expiration:Jan 6, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING IRON DEFICIENCY
Patent:  Start TrialPatent Expiration:Mar 29, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING IRON DEFICIENCY

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
Boehringer Ingelheim
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.